Targeted Biological Effect of An Affitoxin Composed of an HPV16E7 Affibody Fused with Granzyme B (ZHPV16E7-GrB) Against Cervical Cancer In vitro and In vivo

Background: High risk type 16 of human papillomavirus (HPV16) is associated with 50% of cervical cancer, for which reliable targeted therapies are lacking. HPV early protein 7 (E7) is an oncoprotein responsible for cell malignant transformation. In our previous work, a highly specific affibody targeting HPV16E7 (Z HPV16E7 ) was developed. Objective: In order to improve the targeted therapeutic effect, the present study prepared an affitoxin consisting of Z HPV16E7 fused with granzyme B (GrB), namely, Z HPV16E7 -GrB, and evaluated its targeting action in vitro and in vivo. Methods: The Z HPV16E7 -GrB fusion protein was produced in a prokaryotic expression system. The targeted binding properties of the Z HPV16E7 -GrB to the HPV16E7 were confirmed by immunofluorescence assay (IFA) in cervical cancer cell lines, by immunohistochemical assay (IHA) in cervical cancer tissue from clinical specimens and by near-infrared imaging in tumour-bearing mice. The anti- tumour effect on both cervical cancer cells in vitro and tumour-bearing mice in vivo were further evaluated. Results: A 34-kDa Z HPV16E7 -GrB fusion protein was produced in E. coli and displayed the corresponding immunoreactivity. IFA revealed that Z HPV16E7 -GrB bound specifically to HPV16-positive TC-1 and SiHa cells. IHA showed that Z HPV16E7 -GrB also bound specifically to HPV16-positive clinical tissue specimens. In addition, the near-infrared imaging results showed that Z HPV16E7 -GrB was enriched in tumour tissues. Moreover, both the Z HPV16E7 -GrB affitoxin and ZHPV16E7 affibody (without GrB) significantly reduced the proliferation of cervical cancer cells in vitro and tumor-bearing mice in vivo, and the anti-proliferative effect of Z HPV16E7 -GrB was higher than that of the Z HPV16E7 affibody. Conclusions: The affitoxin by coupling the affibody with GrB is a promising targeted therapeutic agent with the dual advantages of the targeted affibody and the GrB cytotoxin.